1. Guideline recommendations for surveillance for hepatocellular carcinoma.
GUIDELINE | INDICATION TO SURVEILANCE | TEST | INTERVAL |
American Association for the Study of Liver Disease (AASLD; (Heimbach 2018)) | Cirrhosis | Abdominal ultrasound alone or plus AFP | 6 months |
European Association for the Study of the Liver with European Organization for Research and Treatment of Cancer (EASL‐EORTC; (EASL‐EORTC 2012; EASL 2018)) | Cirrhosis in Child Pugh stages A and B; cirrhosis in Child C stage awaiting liver transplantation; non‐cirrhotic hepatitis B virus (HBV) carriers with active hepatitis or family history of HCC; non‐cirrhotic chronic hepatitis C with advanced liver fibrosis stage 3 (F3) | Abdominal ultrasound | 6 months 3 to 4 months: people with a nodule less than 1 cm or after resection or loco‐regional therapies |
Asian Pacific Association for the Study of the Liver (APASL; (Omata 2017)) | Cirrhosis and chronic HBV infection at risk of HCC | Abdominal ultrasound with serum AFP | 6 months |
AFP: alpha‐foetoprotein; HCC: hepatocellular carcinoma